Caplacizumab is a therapeutic monoclonal antibody which interferes with binding of platelets to extralong vWF multimers. It is first-line acute treatment option of TTP thrombotic thrombocytopenic purpura. I heard a talk at dgfn2020 and decided to aks the open question, might it be useful for covid19. 3 min answer :))))
Nothing at pubmed, some at pmc by full-text cooccurence of phrases, e.g.
|32454092 2020. Microvascular thrombosis: experimental and clinical implications|